European health regulator recommends approval for GSK's twice yearly asthma drug

Core Viewpoint - The European Medicines Agency has recommended the approval of GSK's add-on drug for treating asthma and a chronic inflammatory sinus condition [1] Company Summary - GSK's new drug is aimed at addressing asthma and chronic inflammatory sinus conditions, indicating a strategic expansion in their respiratory treatment portfolio [1]